Tech Company Financing Transactions
Paterna BioSciences Funding Round
SpringTide Ventures, Divergent Capital and Freya Capital participated in a $6 million Seed funding round for Paterna BioSciences. The round was announced on 10/29/2024.
Transaction Overview
Company Name
Announced On
10/29/2024
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the development of its in vitro spermatogenesis (IVS) technology through preclinical development, as well as to develop its infrastructure, and grow its team.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
2749 East Parleys Way 100
Salt Lake City, UT 84109
USA
Salt Lake City, UT 84109
USA
Phone
Undisclosed
Website
Email Address
Overview
There is currently no effective, FDA-approved therapeutic for male infertility. After a decade of collaboration among the founders, Paterna has deciphered the in vivo environment for spermatogenesis and applied it to in vitro spermatogenesis, facilitating the treatment of male infertility. We started Paterna because our founders wanted to ensure that all couples could have healthy children.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jim Hotaling
Chief Executive Officer
Alex Pastuszak
Chief Financial Officer
Danny Mitchell
Chief Marketing Officer
Jessica Kelley
Chief Operating Officer
Meredith Vadis
Co-Founder
Brad Cairns
VP - Administration
Hollie Chan
Browse more venture capital transactions:
Prev: 10/29/2024: Zinc venture capital transaction
Next: 10/29/2024: Petfolk venture capital transaction
Share this article
News on VC Transactions
We record tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs